Incidence of urinary tract infections in patients with type 2 diabetes receiving ertugliflozin, placebo or active comparator

被引：0
|
作者：
Hickman, M. A. [1 ]
Patel, S. [2 ]
Lauring, B. [2 ]
Terra, S. G. [3 ]
Johnson, S. [4 ]
Huyck, S. [2 ]
Mancuso, J. P. [1 ]
机构：
[1] Pfizer Inc, Groton, CT 06340 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Pfizer Inc, Andover, MA USA
[4] Pfizer Inc, Collegeville, PA USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
630
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [21] Ertugliflozin for treatment of patients with Type 2 diabetes mellitus
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (08) : 747 - 753
  • [22] Risk assessment of urinary tract infections for patients receiving dapagliflozin
    Chen, Pei-Chun
    Hsu, Su-Han
    Chen, Yenming J.
    Ho, Wen-Hsien
    Hsu, Chun-Po
    JOURNAL OF INTELLIGENT & FUZZY SYSTEMS, 2019, 36 (02) : 1041 - 1048
  • [23] A clinical prediction rule for urinary tract infections in patients with type 2 diabetes mellitus in primary care
    Venmans, L. M. A. J.
    Gorter, K. J.
    Rutten, G. E. H. M.
    Schellevis, F. G.
    Hoepelman, A. I. M.
    Hak, E.
    EPIDEMIOLOGY AND INFECTION, 2009, 137 (02): : 166 - 172
  • [24] Prediction of complicated urinary tract infections in patients with type 2 diabetes: a questionnaire study in primary care
    Venmans, Leonie M. A. J.
    Sloof, Marian
    Hak, Eelko
    Gorter, Kees J.
    Rutten, Guy E. H. M.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2007, 22 (01) : 49 - 54
  • [25] Type 2 Diabetes and Incidence of Urinary Tract Infections (UTIs). Experience from the General Practice Research Database (GPRD)
    Hirji, Ishan
    Guo, Zhenchao
    Andersson, Susan
    Hammar, Niklas
    Caminero, Andres Gomez
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S119 - S119
  • [26] Prediction of complicated urinary tract infections in patients with type 2 diabetes: a questionnaire study in primary care
    Leonie M. A. J. Venmans
    Marian Sloof
    Eelko Hak
    Kees J. Gorter
    Guy E. H. M. Rutten
    European Journal of Epidemiology, 2007, 22 : 49 - 54
  • [27] Evaluation of fractures, bone mineral density and bone biomarkers in patients with type 2 diabetes receiving ertugliflozin
    Masiukiewicz, U.
    Hickman, A.
    Frederich, R.
    Patel, S.
    Gallo, S.
    Lauring, B.
    Terra, S. G.
    Johnson, S.
    Huyck, S.
    Mancuso, J. P.
    DIABETOLOGIA, 2018, 61 : S306 - S307
  • [28] Association of Incidence of Urinary Tract Infections (UTI) and Genitourinary Tract Infections (GTI) with Duration of SGLT2i in Type 2 Diabetes Mellitus Patients-A Pan-India Study
    Singh, Akashkumar N.
    Singh, Nagendra K.
    Gupta, Arvind
    Phatak, Sanjeev R.
    DIABETES, 2024, 73
  • [29] Urinary tract infections in patients with diabetes treated with dapagliflozin
    Johnsson, Kristina M.
    Ptaszynska, Agata
    Schmitz, Bridget
    Sugg, Jennifer
    Parikh, Shamik J.
    List, James F.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (05) : 473 - 478
  • [30] Urinary Tract Infections in Patients with Type 1 and Type 2 Diabetes: Etiology, Resistance to Antibacterial Chemicals and Virulence Features
    Mitache, Mihaela Magdalena
    Curutiu, Carmen
    Rusu, Elena
    Bahna, Ramona
    Ditu, Mara
    Moldovan, Horatiu
    Hancu, Violeta
    Chifiriuc, Mariana Carmen
    REVISTA DE CHIMIE, 2017, 68 (03): : 566 - 569
12345